Two weeks of liraglutide pretreatment did not prevent doxorubicin-induced acute cardiotoxicity in rats, despite GLP-1 agonists' known anti-inflammatory and antioxidant properties.
No protectionliraglutide failed to improve any measure of doxorubicin-induced cardiotoxicity
What the researchers found
Liraglutide pretreatment (0.6 mg/kg daily for 2 weeks) did not improve any echocardiographic, functional, or molecular measure of doxorubicin-induced acute cardiotoxicity in rats.
Why it matters
This negative result is important — it tempers enthusiasm about repurposing GLP-1 agonists as cardioprotective agents during cancer chemotherapy and highlights that GLP-1's known anti-inflammatory effects don't necessarily translate to all types of cardiac injury.
The numbers in context
60 male Wistar rats; 4 groups (15 per group); control, doxorubicin alone, liraglutide alone, doxorubicin + liraglutide.
How the study worked
Controlled animal study with 60 male Wistar rats in four groups (Control, Doxorubicin, Liraglutide, Doxorubicin+Liraglutide), with echocardiography, isolated heart studies, and myocardial protein expression analysis 48 hours after doxorubicin.
Who was studied
Male Wistar rats
What this study cannot tell us
Acute single-dose doxorubicin model may not represent clinical protocols (which use multiple lower doses); only one liraglutide dose tested; 2-week pretreatment may be insufficient; rat model may not predict human response; 48-hour endpoint may miss delayed protective effects.
How to read the evidence
Moderate preclinical evidence from a well-designed, adequately powered rat study. The negative finding is informative but limited by the acute high-dose doxorubicin model.
When this study was published
Published in 2024, contributing a negative result to the growing literature on GLP-1 cardioprotection.
The bigger picture
Negative studies are essential for evidence-based medicine. While GLP-1 agonists show cardiovascular benefits in many contexts, this study demonstrates they cannot protect against all forms of heart damage, helping define the boundaries of their cardioprotective potential.
Questions still open
- Would longer liraglutide pretreatment or concurrent administration produce different results?
- Do other GLP-1 agonists (semaglutide, tirzepatide) show similar negative results against doxorubicin cardiotoxicity?
- Could GLP-1 agonists protect against chronic, lower-dose doxorubicin protocols used clinically?
Common questions
Can liraglutide protect your heart from chemotherapy damage?
Why does this negative result matter?
Read the original research
Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.
International journal of molecular sciences, 25(11)
Citation
Tonon, Carolina R; Monte, Marina G; Balin, Paola S; Fujimori, Anderson S S; Ribeiro, Ana Paula D; Ferreira, Natália F; Vieira, Nayane M; Cabral, Ronny P; Okoshi, Marina P; Okoshi, Katashi; Zornoff, Leonardo A M; Minicucci, Marcos F; Paiva, Sergio A R; Gomes, Mariana J; Polegato, Bertha F. (2024). Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.. International journal of molecular sciences, 25(11). https://doi.org/10.3390/ijms25115833